BRUSSELS, Nov 25 (KUNA) -- The European Medicines Agency (EMA), Thursday, recommended granting an extension of indication for the COVID-19 vaccine Comirnaty to include use in children aged five to 11.
The vaccine, developed by BioNTech and Pfizer, is already approved for use in adults and children aged 12 and above, said EMA in a press release in Amsterdam where it is based.
In children from five to 11 years of age, the dose of Comirnaty will be lower than that used in people aged 12 and above (10 mg compared with 30 mg).
The EMA concluded that the benefits of Comirnaty in children aged 5 to 11 outweigh the risks, particularly in those with conditions that increase the risk of severe COVID-19.
It will now send its recommendation to the European Commission, which will issue a final decision. (end)